Kornimate/medical-research-clean huggingface dataset:
blood glucose and body fat regulatory effect of peanut skin extract

Conditions: Obesity

Summary: the regulatory effects of the peanut skin extract (sugarlock®) on body fat and blood glucose was demonstrated in a double-blind, placebo-controlled study. .

peanut skins, a by-product of peanut processing industry, is usually discarded as a waste in despite of the high content of phenolic compounds. polyphenol extract from peanut skins has been demonstrated to inhibit α-amylase activity in vitro. hence, the aim of this study was to evaluate the regulatory effects of the peanut skin extract on blood glucose and body fat by a double-blind, placebo-controlled, clinical study. subjects with simple obesity (body mass index \[bmi\] ≥ 27 or body fat ≥ 30%) ingested 4 sugarlock® (n = 16) capsules or placebo (n = 14) a day for a total of 6 weeks. anthropometric measurements (body weight, body fat, blood pressure) and blood biochemical markers including fasting blood glucose (fbg), albumin, total cholesterol (tc), triglyceride (tg), hdl-c, ldl-c, creatinine (cr), blood urea nitrogen (bun), ast, alt were examined every three weeks. also, 5 subjects were randomly selected for mri scans to examine the distribution and thickness of abdominal fat layers before and after the trial.

Eligibility criteria:
inclusion criteria: * adults ages 20-70 years; * body mass index (bmi) ≥ 27 or body fat ≥ 30; * no history of serious diseases associated with heart, liver, kidney, endocrine systems or other organs; * no drugs consumption. exclusion criteria: * bmi \>35; * alcoholic; * us-controlled diabetics; * stoke in past one year; * high blood pressure; * mental diseases or melancholia; * pregency or breast-feeding a child.

Keywords: peanut skin body fat blood glucose waistline body weight
virtual physical activity for type 1 diabetes

Conditions: Type 1 Diabetes

Summary: a virtual group of teens with type 1 diabetes, led by young adults with type 1 diabetes, will play active videogames and discuss activity and health. this study will evaluate the program for feasibility and user satisfaction.


Eligibility criteria:
inclusion criteria: * age of 14-19 years * diagnosis of type 1 diabetes or other absolute insulin deficiency diabetes for ≥6 months * inadequate moderate-to-vigorous physical activity levels (defined as ≤3 days per week achieving ≥60min daily, which is ≤50% of the recommended 7 days per week) * english literacy * own a continuous glucose monitor (dexcom g4, g5, g6 \[san diego, ca\], abbott freestyle libre 2, 14-day \[chicago, il\], medtronic guardian 3, enlite \[dublin, ireland\]) with enough supplies for 6 weeks (when available, we will provide these to those who do not own them, in which case they will be considered to meet this criteria). * access to television or computer with hdmi or usb port. * under regular care by a healthcare provider (defined as attending at least one appointment in the past year, plus access to verified 24hr phone number to reach the provider's team for insulin dose adjustments if assistance is needed) exclusion criteria: • a condition or disability besides type 1 diabetes that would preclude participation in group moderate-to-vigorous physical activity (e.g., cerebral palsy, current pregnancy)

Keywords: exercise adolescent video games self-management social support
cytopenias in hospitalized patients of corona virus infection(covid-19) during first and other waves

Conditions: Corona Virus Infection

Summary: demographic, clinical and laboratory data as well as outcome of total 202 covid-19 patients who were polymerase chain reaction (pcr) positive and admitted in fatima memorial hospital, lahore, pakistan, was collected during first and other waves. data of first wave is from may 2020 to july 2020, second wave from early november to mid december 2020 and third wave from mid march to june 2021. investigator analyzed the data on basis of systemic immune inflammatory index (sii) as well hematological parameters of first wave were compared to other waves of covid-19.


Eligibility criteria:
inclusion criteria: * covid-19 positive hospitalized patients * all genders exclusion criteria: * patients with known hematological disorders * patients with known chronic liver disease

Keywords: covid-19 cytopenia thrombocytopenia anemia leucopenia
orthostatic hypotension in children with acute febrile illness

Conditions: Fever; Orthostatic Hypotension

Summary: objective:to determent if children suffering from acute febrile illness has higher rate of orthostatic hypotension compared with children with no febrile illness. design: a prospective cohort study. subjects: children aged 4-18 year with fever (temperature \> 38.) for up to 48 hours, presenting to the pediatric emergency department. interventions: all subjects will have their blood pressure measured in supine position (after 5 minute of rest) and after 3 minute of standing.

orthosatic hypotension describes a condition in which the autonomic nervous system fails to maintain a stable blood pressure in the face of postural change. children presenting to the pediatric ed with fever often describe symptom like syncope, lightheadedness, dizziness, pallor, fatigue and weakness. these symptom may result from orthostatism related to acute febrile illness. we assume that fever may be associated with autonomic changes (e.g. vasodilatation) that can cause orthostatism. objective: to determent if children suffering from acute febrile illness has higher rate of orthostatic hypotension compared with children with no febrile illness. design: a prospective cohort study. subjects: children aged 4-18 year with fever (temperature \> 38.) for up to 48 hours, presenting to the pediatric emergency department. interventions: all subjects will have their blood pressure measured in supine position (after 5 minute of rest) and after 3 minute of standing. data analysis: the proportion of children with orthostatic hypotension in febrile and non febrile patients will be compared using χ2 test. the changes in blood pressure in both groups will be compared using the student t test. assumption: we assumed that the incidence of orthostatism is higher among children with fever, because fever can cause orthostatism. significance: orthostatism can cause syncope which is a potentially dangerous symptom (e.g. head trauma). syncope accounts for 1-3% of hospital admissions in us. the incidence in youths is estimated at about 15%) patients presenting to the ed with syncope may undergo numerous and expensive work up with low diagnostic yield. -understanding that fever itself can cause orthostatism and syncope may help us with precaution and diagnosis. key word: orthostatism, fever children, emergency medicine.

Eligibility criteria:
inclusion criteria: * age: 4-18 year of age. * oral temperature \> 38.0 * duration of fever 6-48 hours exclusion criteria: * treatment with medications that may cause orthostatism. * vomiting or/and diarrhea (more than twice/day). * suspected cns infection. * chronic diseases * unable to give an informed consent

Keywords: orthostatism fever
taurine effect on glycemic, lipidic and inflammatory profile in individuals with type 2 diabetes

Conditions: Diabetes Mellitus, Type 2

Summary: type 2 diabetes mellitus (dm2) is characterized by chronic hyperglycemia, which is a risk factor for comorbidities and death. although conventional pharmacotherapy is effective, some individuals do not reach the glycemic targets, requiring adjuvant therapies. taurine is a semi-essential amino acid with antioxidant and osmoregulatory properties, commonly used as a nutritional supplement. pre-clinical studies show its effectiveness in reducing blood glucose and cholesterol, but there are no well-conducted clinical studies evaluating the effect of taurine on glycated hemoglobin. additionally, animal models showed that taurine had a protective effect from diabetic nephropathy. the hypothesize of this study is that taurine administration improves the glycemic, lipid, inflammatory, and anthropometric parameters in dm2 individuals.

a randomized, double-blind, placebo-controlled clinical trial will be conducted at hospital de clínicas de porto alegre (hcpa), brazil. a total of 94 participants with dm2 will be recruited and randomized on a 1:1 ratio to receive 3 g taurine as a powder for oral suspension, twice per day, for 12 weeks or packets containing placebo. blood will be collected prior to the treatment and after 12 weeks for glycated hemoglobin, fasting glucose, insulinemia, total cholesterol and fractions, triglycerides, c-reactive protein, creatinine, urea, tumor necrosis factor-alpha (tnf-α), interleukin 1 and 6 (il-1 and il-6) measures. urine will be collected at baseline and after 12 weeks for creatine, protein, and albumin measured. anthropometric parameters and a 24-h dietary recall will be monthly investigated. fourteen days before the end of the trial, participants will be connected to a continuous glucose monitoring system for glucose monitoring system for glucose variability evaluation. participants will be contacted by phone weekly to report adverse effects.

Eligibility criteria:
inclusion criteria * female and male individuals, with clinical diagnosis of dm2 for at least 6 months; * age over 30 years; * bmc equal to or above 18.5 kg/m2, without weight change in the last 3 months; * hba1c between 7.5% and 10.5%. exclusion criteria * use of herbal supplements, antioxidants, and multivitamins in the last 3 months; * pregnancy or lactation; * chronic renal failure with glomerular filtration rate calculated by mdrd \< 30 ml/h; * myocardial infarction in the last than 6 months * current neoplasia; * chronic use of glucocorticoids; * bariatric surgery.

Keywords: taurine inflammation glucose metabolism disorders glycated hemoglobin diabetes mellitus, type 2 amino acids
biomarkers in tissue samples from patients with hodgkin lymphoma enrolled on ecog-2496 clinical trial

Conditions: Lymphoma

Summary: rationale: studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer. it may also help doctors find better ways to treat cancer. purpose: this research study is studying biomarkers in tissue samples from patients with hodgkin lymphoma enrolled on ecog-2496 clinical trial.

objectives: * to explore the predictive power of a gene expression-based multi-gene predictor in classical hodgkin lymphoma (chl) with the potential to change clinical practice by basing treatment decisions on biological markers. outline: archived tissue samples are analyzed for gene expression profile using nanostring technology. results are then compared with patients' treatment outcomes, including failure-free survival and overall survival. projected accrual: a total of 306 patients from ecog-2496 (training cohort) and 87 patients treated with abvd in other trials (validation cohort) will be accrued for this study.

Eligibility criteria:
disease characteristics: * training cohort: patients diagnosed with locally extensive and advanced stage classical hodgkin lymphoma (chl) and treated with doxorubicin, bleomycin, vinblastine, and dacarbazine (abvd) or mechlorethamine, doxorubicin hydrochloride, vinblastine, vincristine, bleomycin, etoposide, and prednisone (stanford v) * pretreatment formalin-fixed, paraffin-embedded tissue (ffpet) from patients enrolled on the randomized phase iii ecog-2496 clinical trial * validation cohort: patients with advanced-stage chl treated with abvd at the british columbia cancer agency (bcca) * pretreatment ffpet available patient characteristics: * not specified prior concurrent therapy: * see disease characteristics

Keywords: stage i adult hodgkin lymphoma stage ii adult hodgkin lymphoma stage iii adult hodgkin lymphoma stage iv adult hodgkin lymphoma
healthy weight poster, multi-site study

Conditions: Childhood Obesity

Summary: this is a multi-site, cross-sectional study of 3-8 year old children and their parents presenting for a well-child check. the investigators are assessing whether a novel, educational, exam room poster can effectively prompt parents to ask their pediatricians about their children's weight status and improve parents' perceptions of their children's weight status.

the purpose of this study is to evaluate whether a novel, educational, exam room poster can effectively prompt parents to ask their pediatricians about their children's weight status. exam rooms within clinics will be randomized to either have the poster or not and parents will complete questionnaires assessing weight perception, whether they discussed their child's weight with their physician, and basic demographics. participants who are in exam rooms with a poster will also answer questions specifically about the poster.

Eligibility criteria:
inclusion criteria: * children aged 3-8 years old presenting to pediatric clinic for a well-child visit. * parents of include children who speak english or spanish and are able to complete a written survey. exclusion criteria: * parents that are \<18 years old * children with no documented weight or height for their visit * any medical condition that would affect weight gain or growth such as failure to thrive, congenital heart defect, etc.

Keywords: parental perception, obesity, overweight
mechanistic effects of colchicine in patients with myocardial infarction

Conditions: Myocardial Infarction

Summary: the aim of this study is to determine the immuno-modulatory mechanistic effects of colchicine in patients with myocardial infarction (mi). investigators hypothesize that colchicine exerts its anti-inflammatory properties by switching the metabolism of neutrophils, thereby reducing the expression of adhesion molecules responsible for their recruitment in mi.

this is a pilot study to explore the mechanistic effects of colchicine in patients with mi. the study will be conducted sequentially in 3 parts: 1. blood will be collected from up to 10 healthy volunteers for protocol development. (group 1). 2. blood will be collected from 20 mi patients within 24 hours of presentation at new york university (nyu) langone medical center and bellevue hospital center (bhc). neutrophil adhesion to human aortic endothelial cells, quantitative expression of adhesion molecules on the surface of neutrophils, quantitative levels of adhesion molecules on neutrophils and endothelial cells, and neutrophil metabolism, using a seahorse analyzer will be evaluated pre- and post-addition of in vitro colchicine. (group 2) 3. the standard low-dose loading regimen of colchicine (1.2 mg followed by 0.6 mg one hour later) will be administered to 20 patients with mi at bhc. blood will be collected prior to drug administration, 2 to 3 hours after completion of the colchicine load, and 23 to 24 hours after the completion of the colchicine load. neutrophil adhesion to human aortic endothelial cells, quantitative expression of adhesion molecules on the surface of neutrophils, quantitative levels of adhesion molecules on neutrophils and endothelial cells, and neutrophil metabolism will be evaluated pre- and post-addition of in vitro colchicine (exact markers will be determined based on the results of in viro studies above). (group 3)

Eligibility criteria:
inclusion criteria: * 18 years of age for the healthy volunteer subset. * 18 years of age and within 24 hours of an mi for the mi subset. exclusion criteria: subjects in all 3 groups will be excluded if they meet one of the following criteria * history of myelodysplasia; * use of anti-inflammatory medications, with the exception of aspirin, within 5 half-lives; * medications known to interact with colchicine; * known creatinine clearance \<30 cc/minute (severe kidney disease); * pregnant; or * unable to consent. mi subjects who will have oral colchicine administered will have the following additional exclusion criteria: * history of intolerance to colchicine; * acute or chronic symptoms of diarrhea within 72 hours prior to enrollment; * hemoglobin \<10 g/dl or clinical evidence of active bleeding during the study period.

Keywords: myocardial infarction colchicine anti-inflammatory
cash plus interventions for prevention of acute malnutrition in children under 5 and their mothers in somalia

Conditions: Malnutrition, Child; Wasting Disease; Stunting; Malnutrition; Malnutrition, Mother

Summary: this trial studied different combinations of cash assistance to families that live in food insecure areas of somalia and aimed to understand if this cash assistance provided reduced malnutrition of children and mothers.

this study was a mixed-methods cluster-randomized controlled trial implemented in the bay and hiran regions of somalia to study monthly cash assistance interventions across 3 study arms. the intervention was provided for 6 months and included cash plus social and behavior change communication intervention. the investigators studied which combination of assistance was most effective and cost-effective at reducing and preventing child and maternal malnutrition (wasting, stunting, etc.). enrolled participants were children under 5 and mothers of children under 5. the investigators collected qualitative, quantitative, and cost data to study the intervention across study arms, household experiences with receiving cash, and household factors related to malnutrition. quantitative household data and anthropometry was collected at baseline, 3 months, and 6 months. qualitative data was collected through focus group discussions on health/nutrition topics with mothers and fathers of children under 5 who participated in the study. cost data was collected in consultation with study and program staff to evaluate the cost-efficiency, cost-effectiveness, and societal costs of the intervention. investigators also monitored the local markets for food availability and price fluctuations to understand its impact on malnutrition in the communities where the trial was being implemented.

Eligibility criteria:
inclusion criteria for child participants: * enrolled in save the children cash plus for nutrition program * ages 6-59 months at baseline * mother is enrolled in the study exclusion criteria for child participants: * received treatment for wasting at baseline * had an episode of severe acute malnutrition in the past 12 months inclusion criteria for mothers: * enrolled in save the children cash plus for nutrition program * at least 18 years old at baseline * have a child that is 6-59 months old at baseline * voluntarily willing to participant through signed consent form. exclusion criteria for mothers: * currently receiving treatment for wasting * had an episode of severe acute malnutrition in the past 12 months

Keywords: social behavior change communication cash transfer humanitarian malnutrition wasting somalia
study of the safety and pharmacokinetics of montelukast (mk-0476) in the treatment of japanese pediatric participants with perennial allergic rhinitis (mk-0476-520)

Conditions: Perennial Allergic Rhinitis

Summary: this study will evaluate the safety and pharmacokinetics of montelukast (mk-0476) in the treatment of japanese pediatric participants with perennial allergic rhinitis (par). the primary hypothesis of this study is that montelukast oral granules (og) and chewable tablets (ct) provide appropriate exposure to montelukast in japanese pediatric participants with par.


Eligibility criteria:
inclusion criteria: * weight ≥8 kg * diagnosis of par and has symptoms of par at visit 1 exclusion criteria: * past or present medical history of asthma * diagosis of acute rhinitis, simple rhinitis, rhinitis congestive, rhinitis atrophic, sinusitis with purulent nasal discharge, rhinitis medicamentosa or nonallergic rhinitis (e.g. vasomotor rhinitis, eosinophilic rhinitis) * started hyposensitization therapy or non-specific immunotherapy within 6 months prior to visit 1 * medical history of inferior concha mucosal resection, submucous resection of inferior turbinates or other surgery aimed at reduction and/or modulation of nasal mucosa (including electrocoagulation, cryoextraction or application of trichloroacetic acid) * clinically significant, active disease of the cardiovascular or hematologic systems or uncontrolled hypertension (1 to 5 year olds: \>120/70 mmhg; 6 to 9 year olds: \>130/80 mmhg; 10 to 15 year olds: \>140/85 mmhg) * medical history of stunted growth * serious drug allergy * treated with other clinical study drug within 3 months prior to visit 1
a trial of the jejunal to ileal diversion endoscopic procedure (side-to-side anastomosis)

Conditions: Diabetes

Summary: this is a single center study to assess metabolic effects in subjects after a jejunal to ileal diversion procedure was performed using colonoscopes.

the jejunal to ileal diversion procedure is an adaptation of a biliopancreatic diversion with duodenal switch, which is a surgical procedure used to treat metabolic syndrome conditions. the small bowel diversion of the jejunum into the ileum by creating a single anastomosis just beyond the ligament of trietz will be studied. up to 15 eligible subjects will be enrolled into the trial. enrollment will stop once 10 subjects have undergone the jejunal to ileal diversion procedure.

Eligibility criteria:
inclusion criteria: * 18 to 65 years of age * a bmi ≥ 30 kg/m2 and \< 50 kg/m2 if subject has type 2 diabetes * hba1c ≥ 6.5% and ≤ 9% * fasting plasma glucose greater than 110 mg/dl * treatment with up to 2 oral diabetic medications * able to understand and sign informed consent document * if subject is female, she must commit to not becoming pregnant for 18 months and agree to use of contraceptives during this period exclusion criteria: * any conditions for which endoscopy/colonoscopy would be contraindicated. * congenital or acquired anomalies of the gi tract, including atresias, stenosis or malrotation. * previous abdomino-pelvic surgery that may result in adhesions or anatomical changes that may interfere with placement of the giw device. * diagnosis of type 2 diabetes less than 6 months * more than 2 oral diabetic medications * use of insulin * if on metformin, history of polycystic ovarian syndrome (pcos) * use of dipeptidyl peptidase-4 (dpp-4) inhibitors * use of glp-1 agonists * use of use of alpha-glucosidase inhibitors * type 1 diabetes * unable or unwilling to perform home blood glucose monitoring * history of or suspected gastrointestinal disease (e.g. cirrhosis, inflammatory bowel disease) * history of active malignancy (i.e. not in remission) with the exception of squamous or basal cell carcinoma of the skin * any blood coagulation disorder * implanted cardiac pacemaker, defibrillator or other implanted electric device - ongoing systemic infection * chronic pancreatitis * chronic liver disease of any cause * poorly controlled psychiatric disease (e.g. ongoing major depression, schizophrenia, borderline personality, suicidality, psychosis) * any history of an eating disorder within the past 5 years * pre-existing severe comorbid cardio-respiratory disease (e.g. congestive heart failure, cardiac arrhythmia, coronary artery disease, chronic obstructive lung disease, pulmonary embolism) * uncontrolled hypertension (systolic bp \> 150 mm hg or diastolic bp \> 100 mm hg)